Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$255 Mln
P/E Ratio
--
P/B Ratio
6.64
Industry P/E
--
Debt to Equity
0.04
ROE
-0.24 %
ROCE
-19.8 %
Div. Yield
0 %
Book Value
4.93
EPS
-1.21
CFO
$-22.16 Mln
EBITDA
$-32.14 Mln
Net Profit
$-31.32 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Sanara Medtech Inc (SMTI)
| -11.36 | -9.14 | -10.03 | -7.01 | 0.71 | 24.00 | 12.48 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Sanara Medtech Inc (SMTI)
| -19.08 | -9.67 | 53.98 | -40.78 | 209.94 | 393.87 | -45.49 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 59.17 | 11,278.97 | 26.62 | 8.05 | |
| 62.24 | 6,815.49 | 52.52 | 23.56 | |
| 58.21 | 11,313.41 | 389.73 | 0.76 | |
| 7.56 | 8,821.37 | -- | -3.24 |
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers... CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas. Address: 1200 Summit Avenue, Fort Worth, TX, United States, 76102 Read more
Executive Chairman
Mr. Ronald T. Nixon
Executive Chairman
Mr. Ronald T. Nixon
Headquarters
Fort Worth, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Sanara Medtech Inc (SMTI) stood at $ 88 Mln as on 31-Dec-24
The share price of Sanara Medtech Inc (SMTI) is $29.43 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Sanara Medtech Inc (SMTI) has given a return of 0.71% in the last 3 years.
Sanara Medtech Inc (SMTI) has a market capitalisation of $ 255 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Sanara Medtech Inc (SMTI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Sanara Medtech Inc (SMTI) and enter the required number of quantities and click on buy to purchase the shares of Sanara Medtech Inc (SMTI).
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas. Address: 1200 Summit Avenue, Fort Worth, TX, United States, 76102
The CEO & director of Mr. Ronald T. Nixon. is Sanara Medtech Inc (SMTI), and CFO & Sr. VP is Mr. Ronald T. Nixon.
There is no promoter pledging in Sanara Medtech Inc (SMTI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,131
|
|
|
1,128
|
|
|
882
|
|
|
682
|
| Sanara Medtech Inc (SMTI) | Ratios |
|---|---|
|
Return on equity(%)
|
-22.95
|
|
Operating margin(%)
|
-7.83
|
|
Net Margin(%)
|
-11.15
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Sanara Medtech Inc (SMTI) was $0 Mln.
$0.74
(
